FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096823024> ?p ?o ?g. }

• W2096823024 abstract "The activity of several well-known anti-malarials, including chloroquine (CQ), is attributed to their ability to inhibit the formation of haemozoin (Hz) in the malaria parasite. The formation of inert Hz, or malaria pigment, from toxic haem acquired from the host red blood cell of the parasite during haemoglobin digestion represents a pathway essential for parasite survival. Inhibition of this critical pathway therefore remains a desirable target for novel anti-malarials. A recent publication described the results of a haem fractionation assay used to directly determine haemoglobin, free haem and Hz in Plasmodium falciparum inoculated with CQ. CQ was shown to cause a dose-dependent increase in cellular-free haem that was correlated with decreased parasite survival. The method provided valuable information but was limited due to its low throughput and high demand on parasite starting material. Here, this haem fractionation assay has been successfully adapted to a higher throughput method in 24-well plates, significantly reducing lead times and starting material volumes.All major haem species in P. falciparum trophozoites, isolated through a series of cellular fractionation steps were determined spectrophotometrically in aqueous pyridine (5 % v/v, pH 7.5) as a low spin complex with haematin. Cell counts were determined using a haemocytometer and a rapid novel fluorescent flow cytometry method.A higher throughput haem fractionation assay in 24-well plates, containing at most ten million trophozoites was validated against the original published method using CQ and its robustness was confirmed. It provided a minimum six-fold improvement in productivity and 24-fold reduction in starting material volume. The assay was successfully applied to amodiaquine (AQ), which was shown to inhibit Hz formation, while the antifolate pyrimethamine (PYR) and the mitochondrial electron transporter inhibitor atovaquone (Atov) demonstrated no increase in toxic cellular free haem.This higher throughput cellular haem fractionation assay can easily be applied to novel anti-malarials with a significantly decreased lead time, providing a valuable tool with which to probe the mechanisms of action of both new and established anti-malarials." @default.
• W2096823024 created "2016-06-24" @default.
• W2096823024 creator A5013508569 @default.
• W2096823024 creator A5042702055 @default.
• W2096823024 creator A5046039176 @default.
• W2096823024 creator A5059857190 @default.
• W2096823024 creator A5083216093 @default.
• W2096823024 creator A5084357178 @default.
• W2096823024 date "2015-06-24" @default.
• W2096823024 modified "2023-10-15" @default.
• W2096823024 title "Optimization of a multi-well colorimetric assay to determine haem species in Plasmodium falciparum in the presence of anti-malarials" @default.
• W2096823024 cites W1969503178 @default.
• W2096823024 cites W1973470114 @default.
• W2096823024 cites W1975291257 @default.
• W2096823024 cites W1975398334 @default.
• W2096823024 cites W1993213550 @default.
• W2096823024 cites W1996808398 @default.
• W2096823024 cites W2007509111 @default.
• W2096823024 cites W2018244383 @default.
• W2096823024 cites W2026738166 @default.
• W2096823024 cites W2049368235 @default.
• W2096823024 cites W2055266017 @default.
• W2096823024 cites W2073108357 @default.
• W2096823024 cites W2079639798 @default.
• W2096823024 cites W2100136404 @default.
• W2096823024 cites W2111815242 @default.
• W2096823024 cites W2124773255 @default.
• W2096823024 cites W2128378359 @default.
• W2096823024 cites W2133750711 @default.
• W2096823024 cites W2137181004 @default.
• W2096823024 cites W2138488546 @default.
• W2096823024 cites W2139435291 @default.
• W2096823024 cites W2144450303 @default.
• W2096823024 cites W2156896172 @default.
• W2096823024 cites W2167800280 @default.
• W2096823024 cites W2296263363 @default.
• W2096823024 doi "https://doi.org/10.1186/s12936-015-0729-9" @default.
• W2096823024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4484700" @default.
• W2096823024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26099266" @default.
• W2096823024 hasPublicationYear "2015" @default.
• W2096823024 type Work @default.
• W2096823024 sameAs 2096823024 @default.
• W2096823024 citedByCount "44" @default.
• W2096823024 countsByYear W20968230242016 @default.
• W2096823024 countsByYear W20968230242017 @default.
• W2096823024 countsByYear W20968230242018 @default.
• W2096823024 countsByYear W20968230242019 @default.
• W2096823024 countsByYear W20968230242020 @default.
• W2096823024 countsByYear W20968230242021 @default.
• W2096823024 countsByYear W20968230242022 @default.
• W2096823024 countsByYear W20968230242023 @default.
• W2096823024 crossrefType "journal-article" @default.
• W2096823024 hasAuthorship W2096823024A5013508569 @default.
• W2096823024 hasAuthorship W2096823024A5042702055 @default.
• W2096823024 hasAuthorship W2096823024A5046039176 @default.
• W2096823024 hasAuthorship W2096823024A5059857190 @default.
• W2096823024 hasAuthorship W2096823024A5083216093 @default.
• W2096823024 hasAuthorship W2096823024A5084357178 @default.
• W2096823024 hasBestOaLocation W20968230241 @default.
• W2096823024 hasConcept C136764020 @default.
• W2096823024 hasConcept C153911025 @default.
• W2096823024 hasConcept C185592680 @default.
• W2096823024 hasConcept C19374876 @default.
• W2096823024 hasConcept C203014093 @default.
• W2096823024 hasConcept C2776028358 @default.
• W2096823024 hasConcept C2778048844 @default.
• W2096823024 hasConcept C2778371730 @default.
• W2096823024 hasConcept C41008148 @default.
• W2096823024 hasConcept C43617362 @default.
• W2096823024 hasConcept C553184892 @default.
• W2096823024 hasConcept C55493867 @default.
• W2096823024 hasConcept C71928629 @default.
• W2096823024 hasConcept C86803240 @default.
• W2096823024 hasConcept C97428945 @default.
• W2096823024 hasConceptScore W2096823024C136764020 @default.
• W2096823024 hasConceptScore W2096823024C153911025 @default.
• W2096823024 hasConceptScore W2096823024C185592680 @default.
• W2096823024 hasConceptScore W2096823024C19374876 @default.
• W2096823024 hasConceptScore W2096823024C203014093 @default.
• W2096823024 hasConceptScore W2096823024C2776028358 @default.
• W2096823024 hasConceptScore W2096823024C2778048844 @default.
• W2096823024 hasConceptScore W2096823024C2778371730 @default.
• W2096823024 hasConceptScore W2096823024C41008148 @default.
• W2096823024 hasConceptScore W2096823024C43617362 @default.
• W2096823024 hasConceptScore W2096823024C553184892 @default.
• W2096823024 hasConceptScore W2096823024C55493867 @default.
• W2096823024 hasConceptScore W2096823024C71928629 @default.
• W2096823024 hasConceptScore W2096823024C86803240 @default.
• W2096823024 hasConceptScore W2096823024C97428945 @default.
• W2096823024 hasFunder F4320320671 @default.
• W2096823024 hasFunder F4320320672 @default.
• W2096823024 hasFunder F4320332161 @default.
• W2096823024 hasIssue "1" @default.
• W2096823024 hasLocation W20968230241 @default.
• W2096823024 hasLocation W20968230242 @default.
• W2096823024 hasLocation W20968230243 @default.
• W2096823024 hasLocation W20968230244 @default.
• W2096823024 hasLocation W20968230245 @default.
• W2096823024 hasOpenAccess W2096823024 @default.
• W2096823024 hasPrimaryLocation W20968230241 @default.

• next